See more : Restore plc (RST.L) Income Statement Analysis – Financial Results
Complete financial analysis of TriplePoint Venture Growth BDC Corp. (TPVG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TriplePoint Venture Growth BDC Corp., a leading company in the Asset Management industry within the Financial Services sector.
- Smartvalue Co., Ltd. (9417.T) Income Statement Analysis – Financial Results
- Sanderson Farms, Inc. (SAFM) Income Statement Analysis – Financial Results
- MegaWatt Lithium and Battery Metals Corp. (MEGA.CN) Income Statement Analysis – Financial Results
- Churchill Capital Corp VI (CCVI-WT) Income Statement Analysis – Financial Results
- Quara Finance Co. (9596.SR) Income Statement Analysis – Financial Results
TriplePoint Venture Growth BDC Corp. (TPVG)
About TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp. is a business development company specializing investments in venture capital-backed companies at the growth stage investments. It also provides debt financing to venture growth space companies which includes growth capital loans, secured and customized loans, equipment financings, revolving loans and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company's total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It targeted returns between 10% and 18%. It does not take board seat in the company.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 61.73M | 119.42M | 83.37M | 42.00M | 40.20M | 41.53M | 24.64M | 15.59M | 22.54M | 29.94M |
Cost of Revenue | -75.76M | 24.66M | 24.79M | 23.26M | 18.47M | 15.62M | 13.29M | 9.85M | 11.01M | 0.00 |
Gross Profit | 137.49M | 94.76M | 58.58M | 18.74M | 21.73M | 25.91M | 11.35M | 5.74M | 11.53M | 29.94M |
Gross Profit Ratio | 222.74% | 79.35% | 70.26% | 44.62% | 54.05% | 62.40% | 46.08% | 36.81% | 51.15% | 100.00% |
Research & Development | 0.00 | -0.27 | 1.14 | 0.35 | 0.44 | 0.55 | 0.37 | 0.49 | 0.00 | 0.00 |
General & Administrative | 9.00M | 6.70M | 6.13M | 6.70M | 6.04M | 4.96M | 4.30M | 4.47M | 4.35M | 10.37M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 9.00M | 6.70M | 6.13M | 6.70M | 6.04M | 4.96M | 4.30M | 4.47M | 4.35M | 10.37M |
Other Expenses | -36.07M | 51.42M | 681.00K | 38.76M | 2.40M | 2.55M | 3.63M | 2.58M | 2.67M | 0.00 |
Operating Expenses | -27.07M | 6.70M | 6.81M | 6.70M | 8.44M | 4.96M | 5.41M | 4.47M | 7.02M | 8.12M |
Cost & Expenses | -27.07M | 55.87M | 6.81M | 6.70M | 8.44M | 18.54M | 16.18M | 12.77M | 14.14M | 8.12M |
Interest Income | 133.25M | 116.57M | 82.83M | 88.57M | 70.52M | 62.61M | 50.04M | 41.77M | 39.90M | 4.68M |
Interest Expense | 33.04M | 26.76M | 17.37M | 15.49M | 10.01M | 9.08M | 9.06M | 7.86M | 3.62M | 0.00 |
Depreciation & Amortization | 0.00 | 66.73M | -27.22M | 48.93M | 28.60M | 29.75M | 31.01M | 11.79M | -2.82M | -20.05M |
EBITDA | 0.00 | 0.00 | 0.00 | -12.55M | -6.50M | 45.64M | 28.29M | 18.99M | 19.14M | -5.76M |
EBITDA Ratio | 0.00% | 68.61% | 91.83% | 84.06% | 79.00% | 103.78% | 104.60% | 105.25% | 84.92% | -9.67% |
Operating Income | 73.81M | 90.32M | 76.56M | 35.31M | 31.76M | 34.99M | 26.27M | 23.01M | 21.96M | 20.05M |
Operating Income Ratio | 119.57% | 75.63% | 91.83% | 84.06% | 79.00% | 84.26% | 106.60% | 147.59% | 97.43% | 66.95% |
Total Other Income/Expenses | -113.63M | -62.13M | -3.06M | 23.26M | -14.09M | 1.57M | -7.04M | -11.89M | 0.00 | -5.28M |
Income Before Tax | -39.82M | -20.07M | 76.56M | 35.31M | 31.76M | 36.56M | 19.23M | 11.13M | 15.52M | 17.15M |
Income Before Tax Ratio | -64.51% | -16.81% | 91.83% | 84.06% | 79.00% | 88.05% | 78.03% | 71.36% | 68.87% | 57.28% |
Income Tax Expense | 0.00 | 26.76M | 40.42M | 47.85M | 38.25M | 7.95M | 29.40M | 18.99M | 296.00K | -2.90M |
Net Income | -39.82M | -46.83M | 76.56M | 35.31M | 31.76M | 36.56M | 19.23M | 11.13M | 15.52M | 17.15M |
Net Income Ratio | -64.51% | -39.21% | 91.83% | 84.06% | 79.00% | 88.05% | 78.03% | 71.36% | 68.87% | 57.28% |
EPS | -1.12 | -1.43 | 2.47 | 1.16 | 1.28 | 1.78 | 1.18 | 0.69 | 1.03 | 1.74 |
EPS Diluted | -1.12 | -1.43 | 2.47 | 1.16 | 1.28 | 1.78 | 1.18 | 0.69 | 1.03 | 1.74 |
Weighted Avg Shares Out | 35.71M | 32.69M | 30.94M | 30.57M | 24.84M | 20.49M | 16.32M | 16.16M | 15.04M | 9.87M |
Weighted Avg Shares Out (Dil) | 35.71M | 32.69M | 30.94M | 30.57M | 24.84M | 20.49M | 16.32M | 16.16M | 15.04M | 9.87M |
TriplePoint Venture Growth BDC Corp. to Announce 2023 Fourth Quarter and Fiscal Year Financial Results on Wednesday, March 6, 2024
12% To 18% Dividend Yields In Danger
I'm Getting 14% Dividends On My Last Buy: TriplePoint Venture Growth
Trinity Capital's Outperformance Is Likely To Continue In 2024 Against TriplePoint And S&P 500 (Rating Downgrade)
TriplePoint Venture Growth: This 15% Yield Is A Cautionary Tale
TriplePoint Venture Growth: Who Can Resist The 15% Dividend Yield?
BDC Weekly Review: Is PIK A Cause For Concern?
TRIPLEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating TriplePoint Venture Growth BDC Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
TriplePoint Venture Growth: High Yield Is Sustainable For Now
TriplePoint Venture Growth: Why I'm Moving To The Sidelines
Source: https://incomestatements.info
Category: Stock Reports